NCT05284526

Brief Summary

The objective of this protocol is to obtain on Parkinson's disease more accessible therapeutic targets than deep brain stimulation (HFS-STN), the neurosurgical treatment for this pathology. This study will pave the way for new forms of adaptive processing for the HFS-STN. It could become functionally coupled to a minimalist EEG centred on the motor cortex and to software for decoding, live or slightly delayed, classes of movements performed. On the one hand, this device could be used as a sensor of the quality of the information transmitted by the cortical network, thus allowing the selection of the optimal parameters of the HFS-STN on the basis of the movement decoding score. On the other hand, this device could lead to adapting the HFS-STN treatment over time by regularly calculating the recognition scores of the different movements performed and comparing them to the initial scores.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started May 2022

Shorter than P25 for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 17, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

March 17, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

May 9, 2022

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 9, 2022

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 21, 2023

Completed
Last Updated

August 23, 2023

Status Verified

May 1, 2022

Enrollment Period

Same day

First QC Date

February 17, 2022

Last Update Submit

August 21, 2023

Conditions

Keywords

EEGMontreal Cognitive AssessmentMDS-UPDRS IIIMDS-UPDRS IV

Outcome Measures

Primary Outcomes (1)

  • measure the encoding capacity of the cortical networks of parkinsonian patients, with or without anti-parkinsonian drug treatment, and with or without High-frequency stimulation (HFS) of the subthalamic nucleus (STN).

    comparison of the success scores of motion recognition, obtained by the decoding algorithms, which will highlight differences in the encoding and transmission capabilities of cortical information between the different experimental groups.

    18 months

Study Arms (3)

parkinsonian patients with and without dopaminergic drug treatment

EXPERIMENTAL

Electroencephalogram (EEG) of 10 parkinsonian subjects with and without dopaminergic drug treatment during the preparation and execution of movements

Other: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

parkinsonian patients with and without High-frequency stimulation of the subthalamic nucleus

EXPERIMENTAL

Electroencephalogram (EEG) of 10 parkinsonian subjects with and without High-frequency stimulation (HFS) of the subthalamic nucleus (STN) during the preparation and execution of movements

Other: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

control subjects

ACTIVE COMPARATOR

Electroencephalogram (EEG) of control subjects during the preparation and execution of movements

Other: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

Interventions

electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

control subjectsparkinsonian patients with and without High-frequency stimulation of the subthalamic nucleusparkinsonian patients with and without dopaminergic drug treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients :
  • Patient over 18 years of age
  • Patient meeting the clinical diagnostic criteria for Parkinson's disease (Postuma et al, Mov Dis, 2015)
  • Signed consent to participate in the study
  • Absence of cognitive impairment (MoCA\>24)
  • Affiliation to a French social security scheme
  • Healthy volunteer :
  • Healthy volunteer over 18 years of age
  • Signed consent to participate in the study
  • Absence of cognitive disorders (MoCA\>24)
  • Affiliation to a French social security system

You may not qualify if:

  • Patients :
  • Patient refusal to participate
  • Pregnancy or breastfeeding in progress
  • Participation in another therapeutic interventional study
  • Patient under guardianship or curatorship
  • Person subject to a legal protection measure
  • Healthy volunteers :
  • Refusal of the healthy volunteer to participate
  • Pregnancy or breastfeeding in progress
  • Participation in another therapeutic interventional study.
  • Patient under guardianship or curatorship
  • Person subject to a legal protection measure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

DEGOS

Bobigny, 93009, France

Location

Related Publications (3)

  • Ashkan K, Rogers P, Bergman H, Ughratdar I. Insights into the mechanisms of deep brain stimulation. Nat Rev Neurol. 2017 Sep;13(9):548-554. doi: 10.1038/nrneurol.2017.105. Epub 2017 Jul 28.

    PMID: 28752857BACKGROUND
  • Liao K, Xiao R, Gonzalez J, Ding L. Decoding individual finger movements from one hand using human EEG signals. PLoS One. 2014 Jan 8;9(1):e85192. doi: 10.1371/journal.pone.0085192. eCollection 2014.

    PMID: 24416360BACKGROUND
  • Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995 Jan 14;345(8942):91-5. doi: 10.1016/s0140-6736(95)90062-4.

    PMID: 7815888BACKGROUND

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2022

First Posted

March 17, 2022

Study Start

May 9, 2022

Primary Completion

May 9, 2022

Study Completion

April 21, 2023

Last Updated

August 23, 2023

Record last verified: 2022-05

Locations